SIMULTANEOUS TREATMENT WITH CISPLATIN AND RADIATION-THERAPY FOR ADVANCED SOLID TUMORS - A PILOT-STUDY

Google Scholar
  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (3-4) , 219-222
Abstract
To study the toxicity and efficacy of simultaneous cisplatin chemotherapy and radiation therapy, 13 patients with metastatic solid tumors were treated with cisplatin on a weekly, outpatient basis during palliative radiation therapy. The dose of cisplatin ranged from 20-50 mg/m2 weekly, with most patients receiving 40 mg/m2. Radiation therapy was administered in a variety of dose-fraction schedules. Toxic effects were moderate and consisted of emesis (12 patients), transient elevation of BUN [blood urea nitrogen] (3 patients), myelosuppression (3 patients) and radiation reactions (2 patients). Twelve of 13 irradiated lesions (91%) responded with at least a 50% reduction in biperpendicular diameter. Four of the 6 patients with metastatic melanoma had complete regression of treated lesions; another melanoma patient had a partial response. Responses were also seen in patients with mesothelioma, bladder cancer, squamous cell carcinoma of the head and neck and oat cell lung cancer. Only 1 responding patient has had disease progression in the treated field after 2+ to 7+ mo. of follow-up; 2 other patients have died of disseminated disease. Weekly cisplatin administration during radiotherapy deserves further evaluation, especially in the primary management of unresectable tumors that are responsive to cisplatin alone.

This publication has 1 reference indexed in Scilit: